Core Viewpoint - The agreement between CFFM and Pulsenmore marks a significant advancement in prenatal care, enabling remote monitoring through home ultrasound services, which enhances patient access and reduces unnecessary visits to diagnostic centers [1][5]. Company Overview - Pulsenmore is focused on transforming maternal health with home-use ultrasound technology that connects mothers and healthcare providers remotely, aiming to improve access and continuity of prenatal care [6]. - CFFM is a prenatal diagnostic center in California that specializes in high-risk pregnancies, managing approximately 1,500 pregnancies annually across two locations in the Los Angeles area [3]. Technological Innovation - Pulsenmore's ultrasound system is designed to empower expectant mothers by providing safe, guided access to ultrasound imaging from home or work, while maintaining close clinician involvement throughout the process [4]. - The collaboration with CFFM will facilitate a remote pregnancy monitoring model that prioritizes patient needs, demonstrating the potential of home-based ultrasound as a routine part of medical care [6]. Market Potential - The agreement with CFFM represents Pulsenmore's first commercial venture in the United States, following recent FDA clearance, and is seen as a crucial step in the company's strategic plan to tap into the U.S. market, which holds significant clinical and business opportunities [5].

Company Overview - Pee Safe, founded in 2013, focuses on affordable sanitary solutions and body-friendly products aimed at reducing health and wellness complications for women [5] - The product lineup includes organic cotton tampons, breast pads, panty liners, intimate wash products, wipes, maternity care products, and anti-pollution dust masks [5] - Pee Safe competes with brands such as Sirona, Sanfe, Nua Women, Plush, and major companies like Johnson & Johnson and Procter & Gamble [5] Recent Funding - Pee Safe has secured $32 million (approximately INR 288 crore) in its Series C funding round from OrbiMed, which is backed by Netmeds, through a mix of primary and secondary share sales [3][4] - The investment will be utilized to expand its offline retail presence, enhance brand-led marketing, and accelerate growth in quick commerce and leading marketplaces [3][4] Strategic Goals - The fresh capital will significantly deepen Pee Safe's offline distribution and accelerate momentum in quick commerce and e-commerce, allowing the company to reach more consumers at scale [4] - OrbiMed's Dr. Sunny Sharma and Sumona Chakraborty will join Pee Safe's board as part of the investment deal [4] Industry Insights - The global femtech market was valued at $60.2 billion in 2024 and is projected to grow at a CAGR of 16% over the next decade, indicating strong demand for sanitary and hygienic products [6] - The femtech segment is attracting significant investment due to the high demand for sanitary and hygienic products in the consumer industry [6]